Characteristics and outcomes of COVID-19 patients with and without asthma from the United

Nine databases from the United States, South Korea, Spain, the UK, and the Netherlands contributed data from January to June 2020. The study describes 666,933 diagnosed and 159,552 hospitalized COVID-19 patients, comparing clinical characteristics and outcomes for those with and without asthma. It was authored by Daniel R. Morales of the University of Dundee.

Use Cases

• Compare international asthma prevalence among COVID-19 patients based on reported ranges of 5.2% to 20.5%.
• Analyze comorbidity patterns in COVID-19 asthma patients based on mentioned conditions like hypertension, heart disease, diabetes, and obesity.
• Study mortality and acute respiratory distress syndrome (ARDS) outcomes for hospitalized asthma patients based on reported rates of 2.1-16.9% and 15-30% respectively.
• Investigate asthma exacerbation rates at COVID-19 presentation based on reported frequencies of 1.6–8.6%.

Strengths

• Large-scale cohorts with 666,933 diagnosed and 159,552 hospitalized COVID-19 patients.
• International scope covering data from five countries across two continents.
• Reports specific outcome metrics with confidence intervals, such as asthma prevalence ranges and mortality rates.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying patient-level data is unknown, which may limit suitability assessment.
• Last update date is unknown; freshness unverified.

Provenance

Source

University of Dundee

Collection Method

Aggregated from nine contributing databases using COVID-19 disease codes to define diagnosed and hospitalized cohorts.

Time Range

January 2020 to June 2020

Geography

United States, South Korea, Spain, United Kingdom, Netherlands